IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.975
EU - Europa 9.544
AS - Asia 7.377
SA - Sud America 1.342
AF - Africa 613
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 18
Totale 37.895
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.091
SG - Singapore 4.147
IE - Irlanda 2.648
CN - Cina 2.502
UA - Ucraina 2.382
IT - Italia 2.379
BR - Brasile 1.242
CA - Canada 831
RU - Federazione Russa 682
CI - Costa d'Avorio 404
DE - Germania 307
SE - Svezia 296
GB - Regno Unito 179
IN - India 179
SN - Senegal 137
VN - Vietnam 112
FI - Finlandia 102
FR - Francia 102
CH - Svizzera 86
KR - Corea 79
NL - Olanda 79
UZ - Uzbekistan 64
AT - Austria 55
CZ - Repubblica Ceca 49
BE - Belgio 44
PL - Polonia 44
GR - Grecia 43
LB - Libano 34
BD - Bangladesh 33
AR - Argentina 32
MX - Messico 31
JP - Giappone 29
HK - Hong Kong 28
TR - Turchia 28
IQ - Iraq 22
MA - Marocco 21
EC - Ecuador 20
AU - Australia 19
ES - Italia 18
EU - Europa 18
IR - Iran 17
ZA - Sudafrica 16
JO - Giordania 12
VE - Venezuela 12
IL - Israele 11
PK - Pakistan 11
AZ - Azerbaigian 10
NG - Nigeria 10
AE - Emirati Arabi Uniti 9
BG - Bulgaria 9
CO - Colombia 9
NO - Norvegia 9
PY - Paraguay 9
KZ - Kazakistan 8
TN - Tunisia 8
BO - Bolivia 7
NZ - Nuova Zelanda 7
DO - Repubblica Dominicana 6
EG - Egitto 6
RS - Serbia 6
CL - Cile 5
KE - Kenya 5
KW - Kuwait 5
LT - Lituania 5
PS - Palestinian Territory 5
BH - Bahrain 4
DZ - Algeria 4
PE - Perù 4
PH - Filippine 4
SA - Arabia Saudita 4
TH - Thailandia 4
BB - Barbados 3
HN - Honduras 3
LU - Lussemburgo 3
MY - Malesia 3
PT - Portogallo 3
RO - Romania 3
SI - Slovenia 3
AL - Albania 2
CR - Costa Rica 2
HU - Ungheria 2
ID - Indonesia 2
JM - Giamaica 2
KG - Kirghizistan 2
LK - Sri Lanka 2
OM - Oman 2
PA - Panama 2
SV - El Salvador 2
UY - Uruguay 2
AM - Armenia 1
DK - Danimarca 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
KH - Cambogia 1
NI - Nicaragua 1
NP - Nepal 1
SC - Seychelles 1
Totale 37.893
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.862
Jacksonville 2.638
Dublin 2.631
Singapore 2.507
Chandler 2.135
Boardman 1.118
Chicago 931
Catania 863
Nanjing 752
Cambridge 721
Andover 717
Lawrence 716
Toronto 641
Houston 495
Ashburn 464
Des Moines 424
Abidjan 403
San Mateo 386
Nanchang 262
Wilmington 261
Civitanova Marche 229
Saint Petersburg 182
Shenyang 180
Hebei 177
Ottawa 149
Jiaxing 147
Dakar 137
Changsha 135
Florence 130
Beijing 129
Hefei 125
Tianjin 109
Los Angeles 99
Grafing 96
Kochi 92
Rome 88
São Paulo 88
Dong Ket 87
Seoul 79
Munich 71
Milan 63
Moscow 61
Seattle 56
Washington 56
The Dalles 51
New York 48
Hangzhou 43
Turku 42
Brussels 41
Palermo 41
Den Haag 39
Helsinki 38
Norwalk 37
Kunming 35
Council Bluffs 34
Belo Horizonte 32
Falls Church 32
Pune 30
Jinan 29
Bremen 28
Rio de Janeiro 28
San Francisco 28
Hong Kong 25
Brooklyn 24
Guangzhou 24
Hanoi 23
Brno 22
Messina 22
Lappeenranta 21
Ann Arbor 20
Liberty Lake 20
Bari 19
Tokyo 19
Frankfurt Am Main 18
Porto Alegre 18
Redwood City 18
Zhengzhou 18
Phoenix 17
Boston 16
Brasília 16
Hanover 16
Montreal 16
Ningbo 16
Stockholm 16
Campinas 15
Taizhou 15
Tashkent 15
Augusta 13
Fortaleza 13
Ludwigshafen 13
Mexico City 13
Bernareggio 12
Bronte 12
Curitiba 12
Dallas 12
Edinburgh 12
Turin 12
Amman 11
Ardabil 11
Dhaka 11
Totale 25.974
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 232
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 218
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 166
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 161
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 154
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 135
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 125
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 114
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 114
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 111
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 109
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 101
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 97
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 95
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 93
Il Rasario. Semeiotica medica 93
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 92
Terapia del mieloma multiplo 91
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 91
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 90
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 90
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 89
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 89
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 89
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 89
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 89
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 88
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 88
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 87
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 86
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 86
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 85
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 85
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 85
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 84
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 83
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 83
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 83
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 83
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 83
A snapshot of asparaginase-induced liver insufficiency. 81
Hedgehog signaling pathways in multiple myeloma 80
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 80
Cementoplasty in the management of painful extraspinal bone metastases: our experience 80
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 80
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 80
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 79
Uncommon long-term survival in a patient with chronic myeloid leukemia 79
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 79
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 78
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 78
Acute pre-hepatic portal thrombosis: diagnosis and therapy 78
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 78
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 78
Bone turnover markers in patients with type 1 Gaucher disease 78
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 78
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile 77
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 77
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 76
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 76
Clinical and Endoscopic Presentation of Primary Gastric Lymphoma: An Italian Multicenter Study 76
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 76
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 76
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 75
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 75
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 75
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 74
Lymphoma of the cecum: a case report 74
Effects of imatinib mesylate in osteoblastogenesis 74
Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation 74
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 74
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 74
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML 74
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. 74
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 74
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 74
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 73
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 73
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 73
Angiogenesis in acute myeloid leukemia 72
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 72
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 72
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 72
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 72
Eventi avversi e trigger C12: Stroke in ospedale 72
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 71
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 71
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 71
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 71
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 71
Emangioma, plasmocitoma e mieloma multiplo del rachide 71
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 71
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 70
Use of the word "cured" for cancer patients-implications for patients and physicians: the Siracusa charter 70
Lithium and acute myeloid leukemia. 70
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 70
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 70
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 70
Bortezomib for the treatment of previously untreated multiple myeloma. 69
Eco-doppler spleno-portale in pazienti con splenomegalia linfo o mielo-proliferativa.Confronto con la cirrosi epatica splenomegalica 69
Totale 8.675
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.951 39 382 565 81 1.176 67 541 13 470 8 431 178
2021/20225.177 638 764 22 43 873 42 763 175 524 28 122 1.183
2022/20237.437 744 273 104 503 714 1.386 24 1.267 1.978 58 276 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.810 99 2.092 837 448 2.798 1.044 380 521 1.092 1.402 961 1.136
2025/20263 3 0 0 0 0 0 0 0 0 0 0 0
Totale 38.954